Geert MD - Santhera Pharmaceuticals Chief Officer
| SANN Stock | CHF 12.94 0.34 2.70% |
Executive
Geert MD is Chief Officer of Santhera Pharmaceuticals Holding
| Age | 66 |
| Address | Hohenrainstrasse 24, Pratteln, Switzerland, 4133 |
| Phone | 41 61 906 89 50 |
| Web | https://www.santhera.com |
Santhera Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.266) % which means that it has lost $0.266 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.8814) %, meaning that it generated substantial loss on money invested by shareholders. Santhera Pharmaceuticals' management efficiency ratios could be used to measure how well Santhera Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.61 in 2026. Return On Capital Employed is likely to drop to -0.38 in 2026. At this time, Santhera Pharmaceuticals' Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to climb to about 4.2 M in 2026, whereas Non Current Assets Total are likely to drop slightly above 45.4 M in 2026.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Lior Haalman | S H L | 59 | |
| Martin Schlter | Coltene Holding AG | 54 | |
| Roberto Galli | Newron Pharmaceuticals SpA | N/A | |
| Robert Hendriks | Molecular Partners AG | N/A | |
| Mattias Flodin | Coltene Holding AG | 52 | |
| MD MBA | Molecular Partners AG | 60 | |
| Daniel Steiner | Molecular Partners AG | N/A | |
| Martin Steegmaier | Molecular Partners AG | N/A | |
| Gregor Picard | Coltene Holding AG | 56 | |
| Pamela Trail | Molecular Partners AG | 70 | |
| Yves Joens | Ascom Holding AG | N/A | |
| Ravi MD | Newron Pharmaceuticals SpA | 69 | |
| Renate Gloggner | Molecular Partners AG | 56 | |
| David Arnon | S H L | 56 | |
| Filippo Moriggia | Newron Pharmaceuticals SpA | N/A | |
| Adam Novak | Ascom Holding AG | N/A | |
| Astrid Schafer | Evolva Holding SA | 53 | |
| Guido Gloy | Ascom Holding AG | N/A | |
| Luc Gruner | Evolva Holding SA | 74 | |
| Paul Frey | Coltene Holding AG | 51 | |
| Di Hu | Coltene Holding AG | 49 | |
Management Performance
| Return On Equity | -2.88 | ||||
| Return On Asset | -0.27 |
Santhera Pharmaceuticals Leadership Team
Elected by the shareholders, the Santhera Pharmaceuticals' board of directors comprises two types of representatives: Santhera Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Santhera. The board's role is to monitor Santhera Pharmaceuticals' management team and ensure that shareholders' interests are well served. Santhera Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Santhera Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eva Kalias, Head Communications | ||
| Shabir MD, Chief Officer | ||
| Oliver Kronenberg, Chief Secretary | ||
| Gnther Metz, Head VP | ||
| Oliver Strub, Head Compliance | ||
| Geert MD, Chief Officer | ||
| FCMA CGMA, Chief Officer | ||
| Thomas Meier, Founder Chairman | ||
| Dario Eklund, Chief Officer | ||
| Neville MD, Head Management | ||
| Catherine ACMA, Chief Officer | ||
| Sarah HolmesKlotz, Global Culture | ||
| Marc Schrader, Head Operations |
Santhera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Santhera Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.88 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (1.34) % | ||||
| Operating Margin | (1.48) % | ||||
| Current Valuation | 191.5 M | ||||
| Shares Outstanding | 13.39 M | ||||
| Shares Owned By Insiders | 15.14 % | ||||
| Shares Owned By Institutions | 4.74 % | ||||
| Price To Earning | (7.01) X | ||||
| Price To Book | 6.56 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Santhera Stock Analysis
When running Santhera Pharmaceuticals' price analysis, check to measure Santhera Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santhera Pharmaceuticals is operating at the current time. Most of Santhera Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Santhera Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santhera Pharmaceuticals' price. Additionally, you may evaluate how the addition of Santhera Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.